Your browser doesn't support javascript.
loading
Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity.
Yang, Xinquan; Xiong, Ting; Ning, Dong; Wang, Ti; Zhong, Hongyan; Tang, Shan; Mao, Yongqing; Zhu, Guoqiang; Wang, Daxin.
Afiliação
  • Yang X; Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Xiong T; Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Ning D; Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Wang T; Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu, China.
  • Zhong H; Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu, China.
  • Tang S; Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Mao Y; Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Zhu G; Yangzhou University College of Veterinary Medicine, Yangzhou, China. Electronic address: daxinw2002@sina.com.
  • Wang D; Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu, China. Electronic address: yzgqzhu@yzu.edu.cn.
Toxicol Appl Pharmacol ; 402: 115132, 2020 09 01.
Article em En | MEDLINE | ID: mdl-32659285
Current studies aimed at investigating the association between atorvastatin therapy and insulin resistance (IR) appear to be controversial. IR is considered to be an important contributor to inducing cardiac dysfunction through multiple signals. The paradoxical cardiotoxicity of atorvastatin reported under different conditions suggests that the association between atorvastatin treatment, insulin resistance and cardiac function should be clarified further. In this study, C57BL/6 J male mice were fed a high-fat diet (HD) or standard chow diet (SD) for 12 weeks and subsequently randomly divided into four groups: the SD-Control (SD-C) and HD-Control (HD-C) groups treated with saline for 10 months and the HD-A and HD-A + N groups treated with atorvastatin (20 mg/kg/day) alone or atorvastatin combined with nicotinamide (NAM, 1 g/kg/day) for 10 months. Although no significant changes in systolic function and structure were observed between the four groups of mice at an age of 46 or 58 weeks, respectively, long-term treatment with atorvastatin alone or atorvastatin and NAM combination significantly retarded the HD-induced IR and diastolic dysfunction and attenuated both cardiac and hepatic fibrosis in obese mice possibly by regulating the cleavage of osteopontin and then controlling profibrotic activity. Changes in cardiac function and structure were similar between the HD-A and HD-A + N groups; however, mice in the HD-A + N group exhibited better glucose control and marked reduction in body weight and hepatic lipid accumulation. Thus, these results suggest that long-term treatment with atorvastatin or the combination of atorvastatin and nicotinamide may be alternative therapies due to their beneficial effects on IR and diastolic function.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Niacinamida / Disfunção Ventricular Esquerda / Atorvastatina / Obesidade Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Niacinamida / Disfunção Ventricular Esquerda / Atorvastatina / Obesidade Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article